{"title":"Spexin and Fetuin A in Morbid Obese Children","authors":"Mustafa M. Donma, Orkide Donma","volume":178,"journal":"International Journal of Medical and Health Sciences","pagesStart":300,"pagesEnd":304,"ISSN":"1307-6892","URL":"https:\/\/publications.waset.org\/pdf\/10012215","abstract":"<p>Spexin, expressed in the central nervous system, has attracted much interest in feeding behavior, obesity, diabetes, energy metabolism and cardiovascular functions. Fetuin A is known as the negative acute phase reactant synthesized in the liver. Eosinophils are early indicators of cardiometabolic complications. Patients with elevated platelet count, associated with hypercoagulable state in the body, are also more liable to cardiovascular diseases (CVDs). In this study, the aim is to examine the profiles of spexin and fetuin A concomitant with the course of variations detected in eosinophil as well as platelet counts in morbid obese children. 34 children with normal-body mass index (N-BMI) and 51 morbid obese (MO) children participated in the study. Written-informed consent forms were obtained prior to the study. Institutional ethics committee approved the study protocol. Age- and sex-adjusted BMI percentile tables prepared by World Health Organization were used to classify healthy and obese children. Mean age \u00b1 SEM of the children were 9.3 \u00b1 0.6 years and 10.7 \u00b1 0.5 years in N-BMI and MO groups, respectively. Anthropometric measurements of the children were taken. BMI values were calculated from weight and height values. Blood samples were obtained after an overnight fasting. Routine hematologic and biochemical tests were performed. Within this context, fasting blood glucose (FBG), insulin (INS), triglycerides (TRG), high density lipoprotein-cholesterol (HDL-C) concentrations were measured. Homeostatic model assessment for insulin resistance (HOMA-IR) values were calculated. Spexin and fetuin A levels were determined by enzyme-linked immunosorbent assay. Data were evaluated from the statistical point of view. Statistically significant differences were found between groups in terms of BMI, fat mass index, INS, HOMA-IR and HDL-C. In MO group, all parameters increased as HDL-C decreased. Elevated concentrations in MO group were detected in eosinophils (p &lt; 0.05) and platelets (p &gt; 0.05). Fetuin A levels decreased in MO group (p &gt; 0.05). However, decrease was statistically significant in spexin levels for this group (p &lt; 0.05). In conclusion, these results have suggested that increases in eosinophils and platelets exhibit behavior as cardiovascular risk factors. Decreased fetuin A behaved as a risk factor suitable to increased risk for cardiovascular problems associated with the severity of obesity. Along with increased eosinophils, increased platelets and decreased fetuin A, decreased spexin was the parameter, which reflects best its possible participation in the early development of CVD risk in MO children.<\/p>","references":"[1]\tS. Xu and Y. Xue, \u201cPediatric obesity: Causes, symptoms, prevention and treatment,\u201d Exp. Ther. Med., vol. 11, pp. 15-20, Jan. 2016. \r\n[2]\tA. Ladla, P. Tongkrajai, S. Srisaenpang, P. Siviroj, S. Yutthakasemsunt, S. Tiamkao, V. Chotmongkol and K. Sawanyawisuth, \u201cWhich diagnostic criteria of metabolic syndrome are predictors of cardiovascular diseases in elderly populations?,\u201d J. Clin. Transl. Endocrinol., vol. 23, no. 100248, Mar. 2021. \r\n[3]\tD. J. Rader and G. K. Hovingh, \u201cHDL and cardiovascular disease,\u201d Lancet., vol. 384, no. 9943, pp. 618-625, Aug. 2014.\r\n[4]\tX. Chen, Y. Zhang, Q. Chen, Q. Li, Y. Li and W. Ling, \u201cLower plasma fetuin-A levels are associated with a higher mortality risk in patients with coronary artery disease,\u201d Arterioscler. Thromb. Vasc. Biol., vol. 37, no. 11, pp. 2213-2219, Nov. 2017.\r\n[5]\tM. K. Jensen, T. M. Bartz, K. J. Mukamal, L. Djouss\u00e9, J. R. Kizer, R. P. Tracy, S. J. Zieman, E. B. Rimm, D. S. Siscovick, M. Shlipak and J. H. Ix, \u201cFetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study,\u201d Diabetes Care., vol. 36, no. 5, pp. 1222-1228, May 2013. \r\n[6]\tG. A. Laughlin, K. M. Cummins, C. L. Wassel, L. B. Daniels and J. H. Ix, \u201cThe association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study,\u201d J. Am. Coll. Cardiol., vol. 59, no. 19, pp. 1688-1696, May 2012.\r\n[7]\tS. Kumar, M. J. Hossain, A. Javed, I. J. Kullo and P. B. Balagopal, \u201cRelationship of circulating spexin with markers of cardiovascular disease: a pilot study in adolescents with obesity,\u201d Pediatr. Obes., vol. 13, no. 6, pp. 374-380, Jun. 2018.\r\n[8]\tS-Y. Lv, Y-C. Zhou, X-M. Zhang, W-D. Chen and Y-D. Wang, \u201cEmerging roles of NPQ\/Spexin in physiology and pathology,\u201d Front. Pharmacol., vol. 10, pp. 457, May 2019.\r\n[9]\tL. Toll, T. V. Khroyan, K. Sonmez, A. Ozawa, I. Lindberg, J. P. McLaughlin, S. O. Eans, A. A. Shahien and D. R. Kapusta, \u201cPeptides derived from the prohormone proNPQ\/spexin are potent central modulators of cardiovascular and renal function and nociception,\u201d FASEB J., vol. 26, no. 2, pp. 947\u2013954, Feb. 2012.\r\n[10]\tM. Ke\u00e7eba\u015f, S. G\u00fcll\u00fcl\u00fc, S. Sa\u011f, F. Be\u015fli, E. A\u00e7ikg\u00f6z, E. Sarand\u00f6l and A. Aydinlar, \u201cSerum fetuin-A levels in patients with systolic heart failure,\u201d Acta Cardiol., vol. 69, no. 4, pp. 399-405, Aug. 2014.\r\n[11]\tA. Aky\u00fcz, \u201cAssociation of Fetuin-A with Carotid Intima-Media Thickness and Vascular Diseases\u201d, In: Patel V., Preedy V. (eds) Biomarkers in Cardiovascular Disease. Biomarkers in Disease: Methods, Discoveries and Applications, Springer, Dordrecht., 2016.\r\n[12]\tM. Minas, P. Mystridou, P. Georgoulias, S. Pournaras, K. Kostikas and K. I. Gourgoulianis, \u201cFetuin-A is associated with disease severity and exacerbation frequency in patients with COPD,\u201d COPD., vol. 10, no. 1, pp. 28-34, Feb. 2013.\r\n[13]\tM. Keskin, C. Culha, N. E. Gulcelik, E. Ademoglu, A. Keskin, and Y. Aral, \u201cFetuin-A levels determine cardiovascular risk in young diabetic patients,\u201d Biomed. Res. India., vol. 28, no. 15, pp. 6767-6772, 2017.\r\n[14]\tA. Khadir, S. Kavalakatt, D. Madhu, S. Devarajan, J. Abubaker, F. Al-Mulla and A. Tiss, \u201cSpexin as an indicator of beneficial effects of exercise in human obesity and diabetes,\u201d Sci. Rep., vol. 10, no. 1, pp. 10635, Jun. 2020.\r\n[15]\tS. Lv, Y. Zhou, Y. Feng, X. Zhang, X. Wang, Y. Yang and X Wang, \u201cPeripheral spexin inhibited food intake in mice,\u201d Int. J. Endocrinol., vol. 2020, no. 4913785, Aug 2020.\r\n[16]\tK. Abd El-Fattah Abul-Fadle, N. El-Huda A. Mohammed, R. M. Al-Sayed, M. M. Abdul-Rahman and A. I. Farag, \u201cEffect of spexin treatment on cardiometabolic changes in obese type 2 diabetic rats,\u201d Al-Azhar Med. J., vol. 49, no. 2, pp.735-758, 2020.\r\n[17]\tR. Kelishadi, M. Hashemipour, P. Ashtijou, P. Mirmoghtadaee, P. Poursafa, N. Khavarian, and S. Ghatrehsamani, \u201cAssociation of cell blood counts and cardiometabolic risk factors among young obese children,\u201d Saudi Med. J., vol. 31, no. 4, pp. 406-412, Apr. 2010.\r\n[18]\tK. Sakai, S. Inoue, T. Matsuyama, M. Takei, H. Ota, T. Katagiri, and Y. Koboyashi, \u201cEosinophils may be involved in thrombus growth in acute coronary syndrome,\u201d Int. Heart J., vol. 50, no. 3, pp. 267-277, May 2009.\r\n[19]\tA. V. Finn, \u201cEosinophils: an overlooked player in acute myocardial infarction. Editorial,\u201d Coron. Artery Dis., vol. 26, pp. 99-100, March 2015.\r\n[20]\tF. L. Roufosse, \u201cEosinophils: How they contribute to endothelial damage and dysfunction,\u201d Presse Med., vol. 42, pp. 503-507, Apr. 2013. \r\n[21]\tA. Furman-Niedziejko, P. Rostoff, R. Rychlak, K. Golinska-Grzybala, M. Wilczynska-Golonka, M. Golonka, and J. Nessler, \u201cRelationship between abdominal obesity, platelet blood count and mean platelet volume in patients with metabolic syndrome,\u201d Folia Med. Cracov, vol. 54, no.2, pp. 55-64, 2014.\r\n[22]\tO. Donma and M. Donma, \"Eosinophils and platelets: Players of the game in morbid obese boys with metabolic syndrome,\" Int. J. Med. Health Sci., vol. 11, no. 5, pp. 257 \u2013 260, May 2017.\r\n[23]\tO. Donma and M. Donma, \"The potential involvement of platelet indices in insulin resistance in morbid obese children,\" Int. J. Med. Health Sci., vol. 14, no. 3, pp. 85 \u2013 88, Mar. 2020.\r\n[24]\tWorld Health Organization (WHO). The WHO Child Growth Standards. Available at: http:\/\/www.who.int\/childgrowth\/en\/ Accessed on June 10, 2016.\r\n[25]\tM. M. Donma, S. D. Erselcan, A. Yilmaz, S. Guzel and O. Donma, \u201cThe evaluation of new generation inflammatory markers in children with morbid obesity and metabolic syndrome,\u201d Nam. Kem. Med. J., vol. 8, no. 3, pp.479-488, Dec. 2020.\r\n[26]\tS. A. Aroner, D. E. St-Jules, K. J. Mukamal, R. Katz, M. G. Shlipak, M. H. Criqui, B. Kestenbaum, D. S. Siscovick, I. H. de Boer, N. S. Jenny, M. J. Budoff, J. H. Ix and MK Jensen \u201cFetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis,\u201d Atherosclerosis., vol. 248, pp. 224-229, May 2016.\r\n[27]\tL. E. Laugsand, J. H. Ix, T. M. Bartz, L. Djousse, J. R. Kizer, R. P. Tracy, A. Dehghan, K. Rexrode, O. L. Lopez, E. B. Rimm, D. S. Siscovick, C. J. O'Donnell, A. Newman, K. J. Mukamal and M. K. Jensen, \u201cFetuin-A and risk of coronary heart disease: A Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies,\u201d Atherosclerosis., vol. 243, no. 1, pp. 44-52, Nov. 2015.\r\n[28]\tK. T\u00fcrkmen, H. Kay\u0131k\u00e7\u0131o\u011flu, O. \u00d6zbek, A. GaIpov, F. H. Yerlikaya, A. Toker and H. Z. Tonbul, \u201cRelationship between fetuin-A, inflammation, coronary artery calcification in hemodialysis and peritoneal dialysis patients,\u201d Turk. Neph. Dial. Transpl., vol. 21, no. 2, pp. 111-117, 2012.\r\n[29]\tK. Mori, Y. Ikari, S. Jono, M. Emoto, A. Shioi, H. Koyama, T. Shoji, E. Ishimura, M. Inaba, K. Hara and Y. Nishizawa, \u201cFetuin-A is associated with calcified coronary artery disease,\u201d Coron. Artery Dis., vol. 21, no. 5, pp. 281-285, Aug. 2010.\r\n[30]\tM. Behrooz, E. Vaghef-Mehrabany and A. Ostadrahimi, \u201cDifferent spexin level in obese vs normal weight children and its relationship with obesity related risk factors,\u201d Nutr. Metab. Cardiovasc. Dis., vol. 30, no. 4, pp. 674-682, Apr. 2020.\r\n[31]\tT. Chen, F. Wang, Z. Chu, L. Sun, H. Lv, W. Zhou, J. Shen, L. Chen and M. Hou, \u201cCirculating spexin decreased and negatively correlated with systemic insulin sensitivity and pancreatic \u03b2 cell function in obese children,\u201d Ann. Nutr. Metab., vol. 74, no. 2, pp. 125-131, 2019.\r\n[32]\tG. A. Ilhan, and B. Yildizhan, \u201cSpexin as a new metabolic biomarker in women with polycystic ovary syndrome,\u201d Fert. Ster., vol. 110, no. 4, e118, Sept. 2018.","publisher":"World Academy of Science, Engineering and Technology","index":"Open Science Index 178, 2021"}